Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets approved by the U.S. Food and Drug Administration (USFDA).“This launch is a testament to our core strengths in areas of research and development and intellectual property,” says Marc Kikuchi, Chief Executive Officer, North America Generics. “We are excited to be a part of forming the first generic market for Vimovo ® Tablets and to provide an affordable treatment alternative for patients.” The Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets brand had U.S. sales of approximately $414 million MAT for the most recent twelve months ending in December 2019 according to IQVIA Health*.Dr. Reddy’s Naproxen and E...
Bengaluru: Another quarter and another downward revision in growth. Infosys Ltd is expected by at least three brokerages to scale down its full-year dollar revenue growth for the third time this year when India’s second-largest software firm declares its third quarter results on Friday. This is not surprising, considering the negative cross currency impact and also partially, on account of management’s inability to give a firm guidance. Still, 2015-16 is turning out to be roller-coaster ride for Infosys chief executive officer (CEO) Vishal Sikka. Till a year ago, Sikka seemed to have settled well and appeared to be enjoying his job (from playing cricket with employees in Mysuru to the after-results parties with senior management ranks). By December, Sikka came across as a different boss, unhappy with the progress made by the company, and heard telling his colleagues how he has been unable to implement things he had planned when he took over the current job in August 2014. I...
Comments
Post a Comment